On Nov. 1, 2021, Novavax and Serum Institute of India announced that the National Agency of Drug and Food Control of the Republic of Indonesia (Badan POM) had granted emergency use authorization (EUA) for Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant.

It will be manufactured by SII in India and marketed by SII in Indonesia under the brand name COVOVAXﾙ.